Imatinib Viatris

Imatinib, the active ingredient in Imatinib Viatris, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It treats chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia, gastrointestinal stromal tumor, systemic mastocytosis and dermatofibrosarcoma protuberans in adult patients.

GNH USA supplies Imatinib Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Imatinib acts on malignant cells driven by specific tyrosine‑kinase pathways, providing targeted therapy for several hematologic and solid tumours. - Chronic myeloid leukemia: suppresses BCR‑ABL‑driven proliferation and improves long‑term survival. - Philadelphia chromosome‑positive acute lymphoblastic leukemia: blocks leukemic blast growth and facilitates remission. - Gastrointestinal stromal tumor: inhibits c‑KIT and PDGFR signaling to reduce tumor size. - Systemic mastocytosis: curtails abnormal mast cell proliferation. - Dermatofibrosarcoma protuberans: interferes with PDGFR‑driven tumor growth.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Edema: peripheral swelling, often in the ankles. - Fatigue: generalized tiredness. - Muscle cramps: intermittent skeletal muscle discomfort. - Diarrhea: loose stools. - Rash: mild skin eruptions.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Cardiotoxicity: decreased left‑ventricular ejection fraction. - Severe neutropenia: marked reduction in white blood cells. - Hemorrhage: bleeding tendencies. - Pulmonary arterial hypertension: increased pulmonary pressure. - Anaphylaxis: rare severe allergic reaction.

Patients should be monitored for organ function and potential toxicities before and during therapy. - Baseline labs: obtain complete blood count, liver and renal function tests. - Cardiac assessment: evaluate ejection fraction in patients with cardiac risk. - Drug interactions: review concomitant medications for CYP3A4 inhibitors/inducers. - Pregnancy and lactation: discuss risks with a qualified healthcare professional. - Storage: Store below 25°C: keep in the original container, protect from moisture and light.

Imatinib may interact with several drug classes, altering efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase imatinib exposure. - Strong CYP3A4 inducers (e.g., rifampin): may reduce therapeutic levels.

Moderate Interactions (Monitor Closely): - Acid‑reducing agents (e.g., proton pump inhibitors): may affect absorption. - Anticoagulants (e.g., warfarin): may increase bleeding risk. - Vaccines (live attenuated): potential reduced efficacy. - Concomitant chemotherapy agents: may enhance myelosuppression.